Core Viewpoint - The report emphasizes the sustained high growth in the innovative pharmaceutical and medical device sectors, recommending continued investment in these areas [1]. Investment Highlights - The report maintains a recommendation for innovative pharmaceuticals and medical devices, highlighting the potential for value re-evaluation in the Pharma sector, with specific buy ratings for companies such as 恒瑞医药, 翰森制药, 三生制药, and 华东医药 [2]. - It continues to recommend Biopharma/Biotech companies that are gradually realizing their innovative pipelines and entering a performance growth phase, with buy ratings for 科伦博泰生物, 信达生物, 康方生物, 新诺威, 映恩生物, 京新药业, 微芯生物, 特宝生物, 我武生物, and 来凯医药 [2]. - The report also suggests investment in CXO and upstream pharmaceutical companies benefiting from innovation and recovery, maintaining buy ratings for 百普赛斯, 药明康德, 药明合联, 泰格医药, and 美诺华 [2]. - It recommends leading medical device companies expected to recover, with buy ratings for 微创医疗, 联影医疗, and 惠泰医疗 [2]. Market Performance - In the first week of September 2025, the A-share pharmaceutical sector outperformed the broader market, with the SW pharmaceutical and biotech index rising by 1.4% while the Shanghai Composite Index fell by 1.2% [3]. - Within the biopharmaceutical sector, the chemical preparations segment saw a notable increase of 4.5%, while biological products and medical services rose by 1.9% and 1.7%, respectively [3]. - The top-performing stocks included 海辰药业 (+28.7%), 长春高新 (+24.2%), and 百花医药 (+21.3%), while the worst performers were 舒泰神 (-24.0%), 广生堂 (-15.8%), and 塞力医疗 (-15.6%) [3]. - In the Hong Kong market, the healthcare sector also outperformed, with the Hang Seng Healthcare index rising by 7.0% and the biotech index by 7.3%, compared to a 1.4% increase in the Hang Seng Index [3]. - The top gainers in the Hong Kong market were 三叶草生物-B (+99%), 圣诺医药-B (+62%), and 加科思-B (+41%), while the biggest losers included 美中嘉和 (-11%), 科笛-B (-9%), and 思路迪医药股份 (-6%) [3]. - In the US market, the healthcare sector performed in line with the broader market, with the S&P Healthcare Select Sector Index increasing by 0.3%, matching the S&P 500's performance [4]. - The top gainers in the US healthcare sector included 德康医疗 (+7%), 生物基因 (+6%), and 环球健康服务 (+5%), while the largest declines were seen in KENVUE (-10%), REVVITY (-4%), and MOLINA HEALTHCARE (-3%) [4].

Investment Rating - The investment rating for the company is "Accumulate" [5] Core Views - The company achieved a revenue of 176 million yuan in H1 2025, representing a year-on-year growth of 77%, with overseas market revenue growing by 189%. The net loss was 115 million yuan, a significant reduction of 58.9%. The expectation is for continued high growth in revenue due to new product launches and accelerated overseas expansion in 2025 [1][2][4]. Summary by Sections Growth Potential - The company is expected to experience high revenue growth in 2025 driven by both domestic and overseas markets. Overseas orders have seen rapid growth, with over 80 commercial orders and more than 60 installations globally. The company has received CE certification for its surgical robots, allowing for expansion into various surgical fields [2][3]. - The domestic market is also poised for growth as the National Health Commission has increased the number of approved laparoscopic surgical systems significantly, which is expected to boost installations [2]. - New products are being commercialized, including a single-port surgical robot and a remote surgical robot, enhancing market competitiveness [2][3]. Profitability - The company reported a net loss of 115 million yuan in H1 2025, a reduction of 58.9%. With ongoing product rollouts and improved management, the expense ratio is expected to decline, leading to further narrowing of losses in 2025 [4]. Financial Forecast and Valuation - Revenue projections for 2025-2027 are 480 million, 885 million, and 1.302 billion yuan, with year-on-year growth rates of 86.55%, 84.38%, and 47.11% respectively. The expected net profit for 2025 is projected at -258 million yuan, with an EPS of -0.25 yuan [5][11].

Core Viewpoint - The company has successfully developed and mass-produced various electronic materials and medical cable products for the medical device sector, establishing strong partnerships with well-known industry players [1] Group 1: Product Development - The company has independently developed the MT series FEP, polyolefin heat shrink tubing, medical PTFE coated guide wires, and ultra-thin frosted TPU tubes [1] - The medical cable products include blood oxygen lines, core wire guiding branches, and medical data lines [1] Group 2: Industry Partnerships - The company has formed good cooperative relationships with major clients in the medical field, including Lepu Medical, MicroPort Medical, Amphenol Medical, and Mindray Medical [1]

Group 1 - The top three companies with the highest short positions as of August 29 are ZTE Corporation (00763) at 16.47%, COSCO Shipping Holdings (01919) at 13.94%, and CATL (03750) at 13.88% [1][2] - The company with the largest increase in short positions is Ganfeng Lithium (01772), which rose by 2.85% to 12.46% [2][3] - The companies with the largest decrease in short positions include Hisense Home Appliances (00921), which decreased by 3.57% to 4.72%, and WuXi AppTec (02359), which decreased by 2.44% to 11.64% [3][4] Group 2 - The latest short position data shows that the top ten companies with the highest short ratios include China Ping An (02318) at 12.58% and Zijin Mining (02899) at 11.91% [2] - The companies with the most significant increases in short positions also include Huahong Semiconductor (01347) with an increase of 2.56% to 9.73% and Meitu (01357) with an increase of 1.80% to 4.85% [2] - The companies with the most significant decreases in short positions also include Weimob (02013) with a decrease of 1.66% to 9.40% and Linklogis Technology (09959) with a decrease of 1.43% to 2.76% [3][4]

首次公开发行股票并在创业板上市 招股意向书 保荐人（主承销商） 司具有创新投入大、新旧产业融合成功与否存在不确定性、尚处于成长期、经营风 险高、业绩不稳定、退市风险高等特点，投资者面临较大的市场风险。投资者应充 分了解创业板市场的投资风险及本公司所披露的风险因素，审慎作出投资决定。 上海建发致新医疗科技集团 股份有限公司 Shanghai C&D INNOSTIC Medical Technology Group Co., Ltd. （上海市杨浦区杨树浦路 288 号 9 层） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 本次股票发行后拟在创业板市场上市，该市场具有较高的投资风险。创业板公 上海建发致新医疗科技集团股份有限公司 首次公开发行股票并在创业板上市招股意向书 公司已经根据《公司法》《证券法》《上市公司章程指引》，制定了《公司章 程》、三会议事规则、各专门委员会的工作细则、《独立董事工作制度》《董事会秘 书工作细则》，设立了多层次公司治理机构，上述公司治理机构运行、履职情况良好。 公司充分发挥信息系统管理优势，通过自主开发的信息系统整合业务、财务等经 营各环节数据，实现了运营数据的互联 ...

Summary of the Conference Call on the Pharmaceutical Industry Industry Overview - The pharmaceutical industry experienced a profit decline in 2019 due to centralized procurement policies, but demand growth during the pandemic provided some relief. By the first half of 2025, segments such as innovative drugs, pharmaceutical commerce, and CXO showed positive growth, although overall profit levels continued to decline [1][2]. Key Insights and Arguments - **Centralized Procurement Impact**: The centralized procurement of medical consumables began in 2020, leading to negative revenue growth for two consecutive quarters by Q4 2023. However, Q1 2024 saw a return to positive revenue growth, indicating a stabilization in high-value consumables [3][4]. - **Sector Performance**: The chemical preparations sector saw significant revenue declines in Q3 and Q4 of 2023, directly linked to centralized procurement policies. The medical consumables sector has faced revenue and profit pressures since 2022, with in vitro diagnostics (IVD) expected to face challenges starting Q4 2024 [5][6]. - **Future Outlook**: The worst period for the pharmaceutical industry is believed to be over, with price issues being resolved. The price levels are relatively low compared to international markets, and a return to positive growth is anticipated in Q2 2025, potentially leading to an overall positive growth for the year [6][7]. Segment-Specific Insights - **CXO Sector**: The CXO sector is divided into demand-driven and supply-driven enterprises. The latter has benefited from the recovery of overseas markets, while domestic demand-driven companies are beginning to show signs of recovery, as evidenced by the performance of companies like Tigermed and Northstar [7][8]. - **IVD Sector**: The IVD sector is under significant pressure due to policy impacts, with a notable 20% decline in Roche's domestic luminescence business. The overall industry growth rate is approximately -15% [12][13]. - **Medical Equipment**: The medical equipment sector has faced continuous declines since Q4 2023, but signs of recovery were noted in the first half of 2025, with companies like United Imaging and Mindray showing varying degrees of recovery [17][18]. Additional Important Points - **High-Value Consumables**: The high-value consumables sector has undergone multiple rounds of centralized procurement, leading to stable or improved performance for many companies. The gross margin levels for high-value consumables have reached a bottom, with certain products like artificial crystals beginning to see the effects of procurement policies [19][20]. - **Internationalization of Domestic Companies**: Domestic high-value consumables companies are enhancing their international capabilities, with significant clinical data published and FDA certifications obtained for products aimed at the U.S. market [23]. - **Market Competition**: The competition in the luminescence industry is intense, particularly among companies outside the top three, which are resorting to price cuts to gain market share, resulting in significant declines in gross margins [13][14]. This summary encapsulates the key points discussed in the conference call regarding the pharmaceutical industry, highlighting the challenges and opportunities within various segments.

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 微創醫療科學有限公司 呈交日期: 2025年9月4日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00853 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本總額 ...

Core Viewpoint - MicroPort Medical's stock dropped over 7% due to pressure on its main business revenue in the first half of 2025, and the company plans to undergo a business restructuring [1][2] Group 1: Financial Performance - For 1H25, MicroPort Medical reported revenue of $548 million, a year-on-year decrease of 2% [1] - The company recorded a net loss attributable to shareholders of $47 million, an improvement from a loss of $97 million in the same period last year, representing a 52% reduction in loss [1] - Despite revenue challenges, effective cost control and contributions from foreign exchange gains and asset disposals led to a narrower loss than expected [1] Group 2: Business Segment Performance - Major business revenue faced varying degrees of pressure: - Coronary revenue decreased by 2.1%, with domestic revenue remaining stable - Balloon and accessory revenues increased by 38% and 21% respectively - Overseas revenue fell by 10% due to factors like Middle East conflicts and channel adjustments - Orthopedic revenue declined by 3.7% - Arrhythmia management revenue decreased by 1.4% - Revenue from large artery and peripheral segments dropped by 9.2% due to centralized procurement or price reductions - Neurointervention revenue fell by 6.2% [1] Group 3: Strategic Initiatives - The company announced that its board is considering a non-binding proposal for a strategic restructuring of its arrhythmia management business, which may lead to a merger with MicroPort Heart's operations [2] - The company is also planning to sell several properties and other assets, and is in discussions with multiple potential investors for direct investments in its subsidiaries or other assets [2] - These initiatives are expected to help improve the group's debt and cash flow situation [2]

Core Viewpoint - Tianxing Medical is a rapidly advancing company in the sports medicine sector, recently submitting an IPO application to the Hong Kong Stock Exchange after a previous attempt in the STAR Market was terminated. The company faces both opportunities for growth and challenges from centralized procurement policies in the medical device industry [2][5][20]. Group 1: Company Overview - Tianxing Medical was established in 2017 and is headquartered in Beijing. The company focuses on innovative medical devices in the sports medicine field, providing solutions for soft tissue injuries and rehabilitation [7][11]. - The company has undergone significant changes in its ownership structure, with major shareholders including OrbiMed, Junlian Capital, and others. As of August 2023, the post-investment valuation was approximately 3.5 billion RMB [8][7]. - The founder and current chairman, Dong Wenxing, has a background in medical device regulation, which may provide strategic advantages in navigating the industry [9][10]. Group 2: Financial Performance - Tianxing Medical's revenue has shown consistent growth, with figures of 147 million RMB in 2022, 239 million RMB in 2023, and projected 327 million RMB in 2024. Net profits have also increased, reaching 57 million RMB in 2023 [16][17]. - The company has a diverse product matrix, with over 52 approved products and more than 35 in development. The product sales have penetrated over 3,000 hospitals in China [13][16]. - The gross profit margin has fluctuated, with a notable decline in 2024 due to the inclusion of certain products in centralized procurement programs, leading to price reductions [20][19]. Group 3: Market Position and Competition - The sports medicine market in China is still developing, with a market size of approximately 5.4 billion RMB in 2024, compared to a global market size of 6.1 billion USD. The domestic market has significant growth potential [30][33]. - Tianxing Medical holds a market share of about 6.5% in the Chinese sports medicine sector, ranking fourth among all brands and first among domestic brands [33][35]. - The company faces competition from both international players like Smith & Nephew and Johnson & Johnson, as well as domestic companies such as TeliFu and Shanghai Ligetai [33][35]. Group 4: Industry Trends and Challenges - The sports medicine industry is characterized by high concentration, with the top five players accounting for approximately 67.5% of the market share [33]. - The company is under pressure from centralized procurement policies, which may impact pricing and profitability if more products are included in such programs [20][21]. - Continuous innovation and R&D investment are crucial for maintaining competitiveness in the rapidly evolving medical device landscape [22][23].

Summary of MicroPort Medical's Conference Call Company Overview - **Company**: MicroPort Medical - **Period**: First half of 2025 - **Revenue**: Approximately $550 million, a year-on-year decrease of 2% after excluding currency effects, but a quarter-on-quarter increase of 16% in domestic market revenue [2][3][23] Key Financial Metrics - **Gross Margin**: 56.4%, higher than expected [2][23] - **Net Loss**: Reduced by 66% to $36 million [2][25] - **EBITDA**: Increased by 116% to $128 million [2][25] - **Operating Expenses**: Decreased by 14.5% year-on-year [2][23] - **R&D Expenses**: Significantly reduced by 37% [2][23] - **Cash Reserves**: Increased to $1.04 billion [2][27] Business Performance Highlights - **International Business Growth**: Revenue from overseas operations grew by 57.3%, with significant contributions from: - Cardiac intervention overseas revenue up 95% - Neuroscience overseas revenue up 67.4% - MicroPort Robotics overseas market growth nearly tripled [2][3][12] - **Cardiovascular Intervention**: Net profit increased by 64.4%, with a net profit margin of 21% [2][11] - **Orthopedic Business**: Net loss significantly narrowed by 58%, with EBITDA growth of 29% [2][11] - **Heart Valve Business**: Net loss reduced by 96.2%, with TAVI implant volume reaching 2,146 cases [2][21] Strategic Developments - **New Strategic Investor**: Introduction of state-owned Shanshi Capital as a strategic shareholder, expected to enhance business expansion and governance [2][8][39] - **Business Restructuring**: Strategic reorganization of heart rhythm and management businesses to create a unique global cardiac product platform [2][8] Challenges Faced - **Market Pressures**: Challenges include price pressure from domestic centralized procurement, cautious hospital selections due to anti-corruption measures, and delays in new product approvals [4][16] - **Geopolitical Impact**: The orthopedic business faced revenue shortfalls due to US-China tariffs and geopolitical conflicts affecting the supply chain [6][31] Future Outlook - **Revenue Guidance**: Adjusted to high single-digit growth for the year, with cardiovascular business expected to grow by 15% and heart rhythm management adjusted to 6% [5][28][29] - **Innovation and Market Expansion**: Continued focus on innovation, expanding market reach, and enhancing supply chain flexibility [12][45] - **Debt Management**: Plans to reduce debt levels from approximately 70% to around 50% over the next 1-3 years [53][50] R&D and Product Development - **Clinical Trials**: Successful clinical trials for the Firehawk stent, reducing dual antiplatelet therapy duration from 12 months to 1 month for specific patients [10][38] - **New Product Approvals**: The domestic knee joint prosthesis received FDA approval, enhancing competitiveness in overseas markets [13][49] Conclusion - **Overall Performance**: MicroPort Medical demonstrated significant improvements in profitability and operational efficiency despite facing market challenges. The company is well-positioned for future growth through strategic partnerships, innovative product offerings, and a focus on international expansion [2][60]